scholarly journals The Prevalence of Metabolic Syndrome Among Newly Diagnosed Malaysian Breast Cancer Patients

2018 ◽  
Vol 4 (Supplement 2) ◽  
pp. 120s-120s
Author(s):  
S.J. Kiew ◽  
T. Islam ◽  
N.A. Taib ◽  
H.A. Majid ◽  
Keyword(s):  
Breast Cancer ◽  
Metabolic Syndrome ◽  
Waist Circumference ◽  
Cancer Patients ◽  
Body Fat ◽  
Body Fat Percentage ◽  
Newly Diagnosed ◽  
Breast Cancer Patients ◽  
Fat Percentage ◽  
Increased Risk

Background: The incidence of breast cancer has increased in South East Asian (SEA) women. Malaysia has the highest obesity rates in SEA. Malaysian Breast Cancer Survivorship Cohort (MyBCC) study is a hospital-based prospective cohort study that aims to study the association between lifestyle factors and overall survival and quality of life of Malaysian breast cancer patients. Metabolic syndrome (MS) is associated with increasing levels of inflammatory cytokines and leptin that can stimulate cell proliferation through various mechanisms, hence indicating both an increased risk of developing breast cancer and a poorer prognosis. However, there is very scarce information available on the presence of MS among the newly diagnosed breast cancer patients. This is an early report of the presence of MS in the MyBCC study. Aim: We aim to evaluate the presence of MS among newly diagnosed breast cancer patients and to determine the association of MS and sociodemographic factors. Methods: 370 newly diagnosed breast cancer patients were interviewed at baseline. The anthropometric data (waist circumference, hip circumference, body weight, body height and body fat percentage) and also blood for lipid profile and glucose profile were collected. The MS status of the patients was defined using a modified International Diabetes Federation worldwide definition; presence of central obesity (waist circumference ≥ 80 cm) and any of two or more of the following criteria: (i) raised triglyceride with ≥ 1.7 mmol/L, (ii) reduced HDL-cholesterol that < 1.3 mmol/L, (iii) diagnosed with hypertension and (iv) diagnosed with diabetes. Results: Among the 370 breast cancer patients, most were aged 51 years and above (258, 69.7%), were Chinese (180, 48.6%), had secondary school education level (168, 45.4%), had less than RM3500 household income (193, 52.2%) and were postmenopausal (250, 67.6%). Most of the patients were obese or overweight (268, 72.4%) and around half of the patients (190, 51.4%) had high body fat percentage. 140 patients had MS (37.8%). MS was significantly higher among patients aged 61 years and above (59, 42.1%) and 51 to 60 years (50, 35.7%) compared with 20 to 50 years of age group (31, 22.1%) ( P < 0.05). The patients with MS were significantly higher among Chinese ethnicity (57, 40.7%), unemployed (95, 70.4%), and postmenopausal (108, 77.1%) ( P < 0.05). Conclusion: The prevalence of MS is high in newly diagnosed Malaysian breast cancer patients. With longer follow-up, further analysis will be done to look at association with outcomes.

scholarly journals Probiotics for the Treatment of Docetaxel-Related Weight Gain of Breast Cancer Patients—A Single-Center, Randomized, Double-Blind, and Placebo-Controlled Trial

2021 ◽  
Vol 8 ◽  
Author(s):  
Zhang Juan ◽  
Zhang Qing ◽  
Liang Yongping ◽  
Liyuan Qian ◽  
Wei Wu ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Body Weight ◽  
Weight Gain ◽  
Cancer Treatment ◽  
Cancer Patients ◽  
Body Fat ◽  
Breast Cancer Treatment ◽  
Body Fat Percentage ◽  
Breast Cancer Patients ◽  
Fat Percentage

Background: Docetaxel is an important chemotherapy-agent for breast cancer treatment. One of its side-effects is weight gain, which increases the all-cause mortality rate. Considering gut microbiota is one important factor for weight regulation, we hypothesized that probiotics could be potentially used to reduce the docetaxel-related weight gain in breast cancer patients.Methods: From 10/8/2018 to 10/17/2019, 100 breast cancer (Stage I-III) patients underwent four cycles of docetaxel-based chemotherapy were enrolled and randomly assigned to receive probiotics (Bifidobacterium longum, Lactobacillus acidophilus, and Enterococcus faecalis) or placebo (supplementary material of the probiotics capsule) treatment for 84 days with three capsules per time, twice/day. The primary outcome: the changes in body weight and body-fat percentage of the patients were measured by a designated physician using a fat analyzer, and the secondary outcomes: the fasting insulin, plasma glucose, and lipids were directly obtained from the Hospital Information System (HIS); The metabolites were measured using liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS); The fecal microbiome was analyzed using bacterial 16S ribosomal RNA (rRNA) gene sequence. All indicators were measured 1 day before the first cycle of docetaxel-based chemotherapy and 21 days after the last cycle of docetaxel-based chemotherapy.Results: Compared with the placebo group, the probiotic group showed significantly smaller changes in body weight (Mean [SD] 0.77 [2.58] vs. 2.70 [3.08], P = 0.03), body-fat percentage (Mean [SD] 0.04 [1.14] vs. 3.86 [11.09], P = 0.02), and low density lipoprotein (LDL) (Mean [SD]−0.05[0.68] vs. 0.39 [0.58], P = 0.002). Moreover, five of the 340 detected plasma metabolites showed significant differences between the two groups. The change of biliverdin dihydrochloride (B = −0.724, P = 0.02) was inverse correlated with weight gain. One strain of the phylum and three strains of the genus were detected to be significantly different between the two groups. Also, the changes of Bacteroides (B = −0.917, P &lt; 0.001) and Anaerostipes (B = −0.894, P &lt; 0.001) were inverse correlated with the change of LDL.Conclusions: Probiotics supplement during docetaxel-based chemotherapy for breast cancer treatment may help to reduce the increase in body weight, body-fat percentage, plasma LDL, and minimize the metabolic changes and gut dysbacteriosis.Clinical Trial Registration:http://www.chictr.org.cn/showproj.aspx?proj=24294, ChiCTR-INQ-17014181.

scholarly journals Prevalence of Metabolic Syndrome among Breast Cancer Survivors in East Coast of Peninsular Malaysia

2020 ◽  
Author(s):  
Syed Amirfaiz ◽  
Mohd Razif Shahril ◽  
Pei Lin Lua ◽  
Ali Nurnazahiah ◽  
Nor Syamimi Zakarai ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metabolic Syndrome ◽  
Waist Circumference ◽  
Cancer Survivors ◽  
Body Fat ◽  
Breast Cancer Survivors ◽  
East Coast ◽  
Peninsular Malaysia ◽  
Body Fat Percentage ◽  
Fat Percentage

Abstract To date, limited data are available on metabolic syndrome (MetS) prevalence among breast cancer survivors in Malaysia. Therefore, this study was conducted to determine the prevalence of MetS and abnormal MetS components among breast cancer survivors in East Coast of Peninsular Malaysia. This cross-sectional study included 95 breast cancer survivors (age 53.7±7.6 years) who have completed main cancer treatments for ≥6 months. Cancer survivors were recruited from two main government hospitals in Kelantan and Terengganu using a purposive sampling method. According to the Harmonized criteria, the MetS prevalence was 50.5%. Among those with MetS, the most prevalent abnormal metabolic components were triglycerides (91.2%), fasting blood glucose (79.6%) and HDL-c level (78.4%). Except for total cholesterol and LDL-c, all other MetS components were significantly different (p<0.05) between those with and without MetS. Significant differences between MetS and non-MetS groups were found for weight, BMI, waist circumference, body fat percentage and cancer stages (p<0.05). Otherwise, no significant difference was reported in other sociodemographic and clinical parameters between cancer survivors with and without MetS. In conclusion, MetS was highly prevalent among breast cancer survivors in this study, with weight, BMI, waist circumference, body fat percentage and cancer stages significantly affect MetS status.

scholarly journals The Effects of Obesity on Lymphatic Pain and Swelling in Breast Cancer Patients

Biomedicines ◽  
2021 ◽  
Vol 9 (7) ◽  
pp. 818
Author(s):  
Mei Rosemary Fu ◽  
Deborah Axelrod ◽  
Amber Guth ◽  
Melissa L. McTernan ◽  
Jeanna M. Qiu ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Body Fat ◽  
Molecular Mechanisms ◽  
Significant Risk ◽  
Body Fat Percentage ◽  
Symptom Experience ◽  
Breast Cancer Patients ◽  
Fat Percentage ◽  
Arm Swelling

Lymphatic pain and swelling due to lymph fluid accumulation are the most common and debilitating long-term adverse effects of cancer treatment. This study aimed to quantify the effects of obesity on lymphatic pain, arm, and truncal swelling. Methods: A sample of 554 breast cancer patients were enrolled in the study. Body mass index (BMI), body fat percentage, and body fat mass were measured using a bioimpedance device. Obesity was defined as a BMI ≥ 30 kg/m2. The Breast Cancer and Lymphedema Symptom Experience Index was used to measure lymphatic pain, arm, and truncal swelling. Multivariable logistic regression models were used to estimate the odds ratio (OR) with 95% confidence interval (CI) to quantify the effects of obesity. Results: Controlling for clinical and demographic characteristics as well as body fat percentage, obesity had the greatest effects on lymphatic pain (OR 3.49, 95% CI 1.87–6.50; p < 0.001) and arm swelling (OR 3.98, 95% CI 1.82–4.43; p < 0.001). Conclusions: Obesity is a significant risk factor for lymphatic pain and arm swelling in breast cancer patients. Obesity, lymphatic pain, and swelling are inflammatory conditions. Future study should explore the inflammatory pathways and understand the molecular mechanisms to find a cure.

Prognostic significance of HER-2/neu over-expression on the incidence of brain metastasis in newly diagnosed breast cancer

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 649-649 ◽  
Author(s):  
B. S. Abdulkarim ◽  
Z. Gabos ◽  
R. Sinha ◽  
J. Hanson ◽  
N. Chauhan ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Tumor Size ◽  
Univariate Analysis ◽  
Prognostic Significance ◽  
Newly Diagnosed ◽  
Breast Cancer Patients ◽  
Over Expression ◽  
Increased Risk ◽  
Her 2

649 Background: As systemic therapy improves, brain metastases (BM) from breast cancer are becoming increasingly evident. An increased risk of BM in HER-2/neu over-expressing metastatic breast cancer patients has been suggested. However, the relationship between HER-2/neu over-expression and the risk of BM in newly diagnosed breast cancer patients is unknown. Methods: To determine incidence of BM in HER-2/neu over-expressing breast cancer patients, a cohort of patients between 01/1998 and 12/2003 with uniform HER-2/neu testing were identified from a cancer registry. A total of 460 patients with HER-2/neu over-expression and 500 patients with HER-2/neu negative disease were reviewed. Patients were excluded if there was breast cancer diagnosed before 01/1998 or others cancer. A total of 301 HER-2/neu over-expressing and 363 HER-2/neu negative patients were included for this analysis. The association between histological features and the occurrence of BM were evaluated with univariate and multivariate analyses. Results: BM were identified in 8% (24 patients) of HER-2/neu over-expressing breast cancer patients compared to only 1.7% (6 patients) in the HER-2/neu negative patients (hazard ratio 5.15 [2.079–12.78], p=0.0001). In patients with recurrent disease, the proportion of BM for HER-2/neu over-expressing patients was 24% compared to 10% in HER-2/neu negative patients. HER-2/neu over-expression, tumor size >2cm, ≥ 4 nodes positive and grade 2/3 were predictors of BM in univariate analysis. In multivariate analysis, HER-2/neu over-expression and tumor size>2cm were an independent prognostic factors for the development of BM, while hormone receptors expressions was protective (p=0.02). Conclusions: Our population based study show that newly diagnosed HER-2/neu over-expressing breast cancer patients are at significantly increased risk for BM. As most BM occur in HER-2/neu over-expressing patients with systemic metastatic disease, these findings could prompt consideration of brain prophylaxis strategies and/or serial radiologic screening to detect asymptomatic BM. No significant financial relationships to disclose.

Sign in / Sign up

Export Citation Format

Share Document